New obesity classification criteria as a tool for bariatric surgery indication

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 681-703

  De Lorenzo, Antonino ^a,b   Soldati, Laura ^c   Sarlo, Francesca ^d   Calvani, Menotti ^a   Di Lorenzo, Nicola ^b   Di Renzo, Laura ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Adiposopathy; Fat mass; Laparoscopic gastric banding; Metabolically healthy normal weight; Metabolically healthy obese; Metabolically obese normal weight; Metabolically unhealthy obese; Normal weight lean; Normal weight obese; Obesity

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE; AUTACOID;

ADIPOSE TISSUE; BARIATRIC SURGERY; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; BODY SIZE; BODY WEIGHT; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; ETHNICITY; FAT MASS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUCOTOXICITY; HUMAN; INFLAMMATION; LEAN BODY WEIGHT; LIPOTOXICITY; OBESITY; PERSONALIZED MEDICINE; REVIEW; SARCOPENIC OBESITY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TREATMENT INDICATION; ADVERSE EFFECTS; ANTHROPOMETRY; CLASSIFICATION; DECISION SUPPORT SYSTEM; ENERGY METABOLISM; ETHNOLOGY; FEMALE; MALE; METABOLISM; NOMENCLATURE; OBESITY, METABOLICALLY BENIGN; PATHOPHYSIOLOGY; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; SARCOPENIA;

ADIPOKINES; ADIPOSE TISSUE; ADIPOSITY; ANTHROPOMETRY; BARIATRIC SURGERY; BODY WEIGHT; DECISION SUPPORT TECHNIQUES; ENERGY METABOLISM; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; OBESITY; OBESITY, METABOLICALLY BENIGN; PATIENT SELECTION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SARCOPENIA; SEX FACTORS; TERMINOLOGY AS TOPIC;

EID: 84954446518     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.681     Document Type: Review

References (259)

1. American Medical Association. Council on Science and Public Health Report, 2013
2. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253 [PMID: 11234459]
3. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int 2014; 2014: 658913 [PMID: 25110685 DOI: 10.1155/2014/658913]
4. Recognition of Obesity as a Disease. Available from: URL: http://www.npr.org/documents/2013/jun/ama-resolution-besity.pdf
5. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109-117 [PMID: 16622298]
6. Shuldiner AR. Obesity genes and gene-environment-behavior interactions: recommendations for a way forward. Obesity (Silver Spring) 2008; 16 Suppl 3: S79-S81 [PMID: 19037219 DOI: 10.1038/oby.2008.523]
7. Sesti G, Perego L, Cardellini M, Andreozzi F, Ricasoli C, Vedani P, Guzzi V, Marchi M, Paganelli M, Ferla G, Pontiroli AE, Hribal ML, Folli F. Impact of common polymorphisms in candidate genes for insulin resistance and obesity on weight loss of morbidly obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. J Clin Endocrinol Metab 2005; 90: 5064-5069 [PMID: 15985484]
8. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971 [PMID: 18775919 DOI: 10.1093/eurheartj/ehn387]
9. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 2008; 32: 638-644 [PMID: 18974244 DOI: 10.1177/0148607 108325251]
10. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452 [PMID: 8594834]
11. Poirier P. Adiposity and cardiovascular disease: are we using the right defnition of obesity? Eur Heart J 2007; 28: 2047-2048 [PMID: 17673449]
12. Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, Vila N, Ibañez P, Gil MJ, Valentí V, Rotellar F, Ramírez B, Salvador J, Frühbeck G. Body mass index classifcation misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) 2012; 36: 286-294 [PMID: 21587201 DOI: 10.1038/ijo.2011.100]
13. Flegal KM. Commentary: the quest for weight standards. Int J Epidemiol 2010; 39: 963-967 [PMID: 20660171 DOI: 10.1093/ije/dyq124]
14. Sun Q, van Dam RM, Spiegelman D, Heymsfield SB, Willett WC, Hu FB. Comparison of dual-energy X-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am J Epidemiol 2010; 172: 1442-1454 [PMID: 20952596 DOI: 10.1093/aje/kwq306]
15. De Lorenzo A, Bianchi A, Maroni P, Iannarelli A, Di Daniele N, Iacopino L, Di Renzo L. Adiposity rather than BMI determines metabolic risk. Int J Cardiol 2013; 166: 111-117 [PMID: 22088224 DOI: 10.1016/j.ijcard.2011.10.006]
16. Franzosi MG. Should we continue to use BMI as a cardiovascular risk factor? Lancet 2006; 368: 624-625 [PMID: 16920449]
17. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008; 32: 959-966 [PMID: 18283284 DOI: 10.1038/ijo.2008.11]
18. Snitker S. Use of body fatness cutoff points. Mayo Clin Proc 2010; 85: 1057; author reply 1057-1058 [PMID: 21037049 DOI: 10.4065/mcp.2010.0583]
19. De Lorenzo A, Deurenberg P, Pietrantuono M, Di Daniele N, Cervelli V, Andreoli A. How fat is obese? Acta Diabetol 2003; 40 Suppl 1: S254-S257 [PMID: 14618486]
20. De Lorenzo A, Nardi A, Iacopino L, Domino E, Murdolo G, Gavrila C, Minella D, Scapagnini G, Di Renzo L. A new predictive equation for evaluating women body fat percentage and obesity-related cardiovascular disease risk. J Endocrinol Invest 2014; 37: 511-524 [PMID: 24458830 DOI: 10.1007/s40618-013-0048-3]
21. Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, Harris TB, Everhart JE, Schenker N. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr 2009; 89: 500-508 [PMID: 19116329 DOI: 10.3945/ajcn.2008.26847]
22. Li C, Ford ES, Zhao G, Balluz LS, Giles WH. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr 2009; 90: 1457-1465 [PMID: 19812179 DOI: 10.3945/ajcn.2009.28141]
23. Gallagher D, Heymsfeld SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000; 72: 694-701 [PMID: 10966886]
24. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2: 51S-209S [PMID: 9813653]
25. Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, Fraterrigo G, Okunade AL, Patterson BW, Klein S. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest 2015; 125: 787-795 [PMID: 25555214 DOI: 10.1172/JCI78425]
26. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430 [PMID: 15604363]
27. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005; 56: 45-62 [PMID: 15660501]
28. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO. Interleukin-6-defcient mice develop mature-onset obesity. Nat Med 2002; 8: 75-79 [PMID: 11786910]
29. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004; 79: 379-384 [PMID: 14985210]
30. Bombelli M, Facchetti R, Fodri D, Brambilla G, Sega R, Grassi G, Mancia G. Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis 2013; 23: 650-656 [PMID: 22633796 DOI: 10.1016/j.numecd.2012.01.004]
31. Kanaya AM, Vittinghoff E, Shlipak MG, Resnick HE, Visser M, Grady D, Barrett-Connor E. Association of total and central obesity with mortality in postmenopausal women with coronary heart disease. Am J Epidemiol 2003; 158: 1161-1170 [PMID: 14652301]
32. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843-1848 [PMID: 9846779]
33. Tchoukalova YD, Votruba SB, Tchkonia T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci USA 2010; 107: 18226-18231 [PMID: 20921416 DOI: 10.1073/pnas.1005259107]
34. Veilleux A, Caron-Jobin M, Noël S, Laberge PY, Tchernof A. Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes 2011; 60: 1504-1511 [PMID: 21421806 DOI: 10.2337/db10-1039]
35. Tchoukalova YD, Koutsari C, Karpyak MV, Votruba SB, Wendland E, Jensen MD. Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr 2008; 87: 56-63 [PMID: 18175737]
36. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 2005; 1: 39-59 [PMID: 19804060 DOI: 10.1517/14796678.1.1.39]
37. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006; 1: 389-420 [DOI: 10.2217/17460875.1.4.389]
38. Bays H. Adiposopathy, "sick fat, " Ockham's razor, and resolution of the obesity paradox. Curr Atheroscler Rep 2014; 16: 409 [PMID: 24659222 DOI: 10.1007/s11883-014-0409-1]
39. Bays HE, González-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, Rodbard HW. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract 2008; 62: 1474-1483 [PMID: 18681905 DOI: 10.1111/j.1742-1241.2008.01848.x]
40. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343-368 [PMID: 18327995 DOI: 10.1586/14779072.6.3.343]
41. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589 [PMID: 15181027]
42. Kushner RF, Roth JL. Assessment of the obese patient. Endocrinol Metab Clin North Am 2003; 32: 915-933 [PMID: 14711068]
43. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163 [PMID: 14726171]
44. Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients 2013; 5: 2019-2027 [PMID: 23739143 DOI: 10.3390/nu5062019]
45. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008; 28: 1654-1659 [PMID: 18566296 DOI: 10.1161/ATVBAHA.108.170316]
46. Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodés-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049 [PMID: 18356555 DOI: 10.1161/ATVBAHA.107.159228]
47. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435 [PMID: 19706383 DOI: 10.1073/pnas.0904944106]
48. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest 2011; 121: 2094-2101 [PMID: 21633177 DOI: 10.1172/JCI45887]
49. Sam S, Mazzone T. Adipose tissue changes in obesity and the impact on metabolic function. Transl Res 2014; 164: 284-292 [PMID: 24929206 DOI: 10.1016/j.trsl.2014.05.008]
50. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168: 1617-1624 [PMID: 18695075 DOI: 10.1001/archinte.168.15.1617]
51. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Häring HU. Identifcation and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616 [PMID: 18695074 DOI: 10.1001/archinte.168.15.1609]
52. Gealekman O, Guseva N, Hartigan C, Apotheker S, Gorgoglione M, Gurav K, Tran K V, Straubhaar J, Nicoloro S, Czech MP, Thompson M, Perugini RA, Corvera S. Depot-specifc differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011; 123: 186-194 [PMID: 21200001 DOI: 10.1161/CIRCULATIONAHA.110.970145]
53. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158 [PMID: 9877249]
54. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556 [PMID: 15181022]
55. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-99; quiz 920 [PMID: 15867843]
56. Anderson EK, Gutierrez DA, Hasty AH. Adipose tissue recruitment of leukocytes. Curr Opin Lipidol 2010; 21: 172-177 [PMID: 20410821 DOI: 10.1097/MOL.0b013e3283393867]
57. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Infamm 2010; 2010: 513948 [PMID: 20508843 DOI: 10.1155/2010/513948]
58. Perreault M, Roke K, Badawi A, Nielsen DE, Abdelmagid SA, El-Sohemy A, Ma DW, Mutch DM. Plasma levels of 14: 0, 16: 0, 16: 1n-7, and 20: 3n-6 are positively associated, but 18: 0 and 18: 2n-6 are inversely associated with markers of infammation in young healthy adults. Lipids 2014; 49: 255-263 [PMID: 24338596 DOI: 10.1007/s11745-013-3874-3]
59. de Jong AJ, Kloppenburg M, Toes RE, Ioan-Facsinay A. Fatty acids, lipid mediators, and T-cell function. Front Immunol 2014; 5: 483 [PMID: 25352844 DOI: 10.3389/fmmu.2014.00483]
60. Carrera Boada CA, Martínez-Moreno JM. Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit". Nutr Hosp 2013; 28 Suppl 2: 78-87 [PMID: 23834050 DOI: 10.3305/nh.2013.28.sup2.6717]
61. Ross R, Shaw KD, Martel Y, de Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr 1993; 57: 470-475 [PMID: 8460599]
62. Campra JL, Reynolds TB. The hepatic circulation. In: Arias IM, Popper H, Schachter D, Shafritz DA, editors. The liver: biology and pathobiology. New York: Raven Press, 1982: 627-645
63. Shah NR, Braverman ER. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One 2012; 7: e33308 [PMID: 22485140 DOI: 10.1371/journal.pone.0033308]
64. Marcus RL, Addison O, Dibble LE, Foreman KB, Morrell G, Lastayo P. Intramuscular adipose tissue, sarcopenia, and mobility function in older individuals. J Aging Res 2012; 2012: 629637 [PMID: 22500231 DOI: 10.1155/2012/629637]
65. Park HS, Park J Y, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35 [PMID: 15955385]
66. Gustafson B, Hammarstedt A, Andersson CX, Smith U. Infamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276-2283 [PMID: 17823366]
67. Henrichot E, Juge-Aubry CE, Pernin A, Pache JC, Velebit V, Dayer JM, Meda P, Chizzolini C, Meier CA. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 2005; 25: 2594-2599 [PMID: 16195477]
68. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of infammatory mediators. Circulation 2003; 108: 2460-2466 [PMID: 14581396]
69. Yudkin JS, Eringa E, Stehouwer CD. "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005; 365: 1817-1820 [PMID: 15910955]
70. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53: 2735-2740 [PMID: 15504952]
71. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874 [PMID: 12490960]
72. Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ. Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 2002; 115: 879-889 [PMID: 12435426]
73. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512 [PMID: 10335721]
74. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2084-2089 [PMID: 11994345]
75. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808 [PMID: 14679176]
76. Hauner H, Petruschke T, Russ M, Röhrig K, Eckel J. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995; 38: 764-771 [PMID: 7556976]
77. Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID. Association of the TNF-alpha-308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002; 10: 401-407 [PMID: 12006640]
78. Meadows KA, Holly JM, Stewart CE. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulinlike growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 2000; 183: 330-337 [PMID: 10797307]
79. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold KR. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996; 97: 2152-2157 [PMID: 8621806]
80. Argilés JM, López-Soriano J, Almendro V, Busquets S, López-Soriano FJ. Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev 2005; 25: 49-65 [PMID: 15389734]
81. Dahlman I, Arner P. Obesity and polymorphisms in genes regulating human adipose tissue. Int J Obes (Lond) 2007; 31: 1629-1641 [PMID: 17563763]
82. Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, El-Sohemy A. Tumor necrosis factor alpha-238G& gt; A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus. Metabolism 2007; 56: 649-655 [PMID: 17445540]
83. Kroeger KM, Carville KS, Abraham LJ. The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399 [PMID: 9293772]
84. Brand E, Schorr U, Kunz I, Kertmen E, Ringel J, Distler A, Sharma AM. Tumor necrosis factor-alpha-308 G/A polymorphism in obese Caucasians. Int J Obes Relat Metab Disord 2001; 25: 581-585 [PMID: 11319665]
85. Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003; 52: 1872-1876 [PMID: 12829659]
86. Gabay C, Dreyer M, Pellegrinelli N, Chicheportiche R, Meier CA. Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes. J Clin Endocrinol Metab 2001; 86: 783-791 [PMID: 11158047]
87. Um JY, Lee KM, Kim HM. Polymorphism of interleukin-1 receptor antagonist gene and obesity. Clin Chim Acta 2004; 340: 173-177 [PMID: 14734209]
88. Griffn WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specifc polymorphisms in disease risk. Exp Gerontol 2000; 35: 481-487 [PMID: 10959036]
89. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F, Burger D, Dayer JM, Meier CA. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-1110 [PMID: 12716739]
90. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial infammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191: 303-312 [PMID: 10637274]
91. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001; 14: 272-282 [PMID: 11444907]
92. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121 [PMID: 3888754]
93. Bensellam M, Laybutt DR, Jonas JC. The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions. Mol Cell Endocrinol 2012; 364: 1-27 [PMID: 22885162 DOI: 10.1016/j.mce.2012.08.003]
94. Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb) 2013; 23: 266-280 [PMID: 24266296]
95. Chae H, Gilon P. Can Tea Extracts Exert a Protective Effect Against Diabetes by Reducing Oxidative Stress and Decreasing Glucotoxicity in Pancreatic β-Cells? Diabetes Metab J 2015; 39: 27-30 [PMID: 25729709 DOI: 10.4093/dmj.2015.39.1.27]
96. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 Suppl 1: S119-S124 [PMID: 14749276]
97. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812 [PMID: 16823478]
98. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61 [PMID: 18048764]
99. Roma LP, Duprez J, Takahashi HK, Gilon P, Wiederkehr A, Jonas JC. Dynamic measurements of mitochondrial hydrogen peroxide concentration and glutathione redox state in rat pancreatic β-cells using ratiometric fuorescent proteins: confounding effects of pH with HyPer but not roGFP1. Biochem J 2012; 441: 971-978 [PMID: 22050124 DOI: 10.1042/BJ20111770]
100. Ma Z, Wirström T, Borg LA, Larsson-Nyrén G, Hals I, Bondo-Hansen J, Grill V, Björklund A. Diabetes reduces β-cell mitochondria and induces distinct morphological abnormalities, which are reproducible by high glucose in vitro with attendant dysfunction. Islets 2012; 4: 233-242 [PMID: 22854606 DOI: 10.4161/isl.20516]
101. Herchuelz A, Nguidjoe E, Jiang L, Pachera N. β-Cell preservation and regeneration in diabetes by modulation of β-cell Ca? homeostasis. Diabetes Obes Metab 2012; 14 Suppl 3: 136-142 [PMID: 22928574 DOI: 10.1111/j.1463-1326.2012.01649.x]
102. Olefsky JM, Glass CK. Macrophages, infammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246 [PMID: 20148674 DOI: 10.1146/annurev-physiol-021909-135846]
103. Suganami T, Tanaka M, Ogawa Y. Adipose tissue infammation and ectopic lipid accumulation. Endocr J 2012; 59: 849-857 [PMID: 22878669]
104. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281-287 [PMID: 12840659]
105. Hallgren B, Stenhagen S, Svanborg A, Svennerholm L. Gas chromatographic analysis of the fatty acid composition of the plasma lipids in normal and diabetic subjects. J Clin Invest 1960; 39: 1424-1434 [PMID: 13710854]
106. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyörälä K, Penttilä I. Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 1985; 56: 271-281 [PMID: 3902037]
107. Zuniga-Guajardo S, Zinman B. The metabolic response to the euglycemic insulin clamp in type I diabetes and normal humans. Metabolism 1985; 34: 926-930 [PMID: 3900631]
108. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am J Physiol 1994; 266: E600-E605 [PMID: 8178981]
109. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37: 635-46, viii-ix [PMID: 18775356 DOI: 10.1016/j.ecl.2008.06.007]
110. Björntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 1969; 185: 351-356 [PMID: 5806343]
111. OPIE LH, WALFISH PG. Plasma free fatty acid concentrations in obesity. N Engl J Med 1963; 268: 757-760 [PMID: 13940209]
112. Zurier RB, Rossetti RG, Seiler CM, Laposata M. Human peripheral blood T lymphocyte proliferation after activation of the T cell receptor: effects of unsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 371-375 [PMID: 10471124]
113. Lima TM, Kanunfre CC, Pompéia C, Verlengia R, Curi R. Ranking the toxicity of fatty acids on Jurkat and Raji cells by fow cytometric analysis. Toxicol In Vitro 2002; 16: 741-747 [PMID: 12423658]
114. Cury-Boaventura MF, Pompéia C, Curi R. Comparative toxicity of oleic acid and linoleic acid on Jurkat cells. Clin Nutr 2004; 23: 721-732 [PMID: 15297111]
115. Cury-Boaventura MF, Gorjão R, de Lima TM, Newsholme P, Curi R. Comparative toxicity of oleic and linoleic acid on human lymphocytes. Life Sci 2006; 78: 1448-1456 [PMID: 16236329]
116. Gorjão R, Cury-Boaventura MF, de Lima TM, Curi R. Regulation of human lymphocyte proliferation by fatty acids. Cell Biochem Funct 2007; 25: 305-315 [PMID: 17195961]
117. RE: Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Urol 1990; 144: 750-751 [PMID: 2143790 DOI: 10.1002/jcp.22740]
118. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404 [PMID: 23303913 DOI: 10.1152/physrev.00033.2011]
119. Pond CM. An evolutionary and functional view of mammalian adipose tissue. Proc Nutr Soc 1992; 51: 367-377 [PMID: 1480631]
120. Krotkiewski M, Björntorp P, Sjöström L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72: 1150-1162 [PMID: 6350364]
121. Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr 1988; 48: 1351-1361 [PMID: 3202084]
122. Vague J. La différenciation sexuelle; facteur déterminant des formes de l'obésité. Presse Med 1947; 55: 339 [PMID: 18918084]
123. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20-34 [PMID: 13282851]
124. Kissebah AH, Peiris AN. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1989; 5: 83-109 [PMID: 2647436]
125. Després JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, Gagné C, Lupien PJ. The insulin resistance-dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord 1995; 19 Suppl 1: S76-S86 [PMID: 7550542]
126. Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes 1995; 44: 141-146 [PMID: 7859931]
127. Albu JB, Kovera AJ, Johnson JA. Fat distribution and health in obesity. Ann N Y Acad Sci 2000; 904: 491-501 [PMID: 10865794]
128. Grundy SM, Adams-Huet B, Vega GL. Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord 2008; 6: 281-288 [PMID: 18759660 DOI: 10.1089/met.2008.0026]
129. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab 2010; 21: 345-352 [PMID: 20223680 DOI: 10.1016/j.tem.2010.01.009]
130. Katzmarzyk PT, Bray GA, Greenway FL, Johnson WD, Newton RL, Ravussin E, Ryan DH, Bouchard C. Ethnic-specifc BMI and waist circumference thresholds. Obesity (Silver Spring) 2011; 19: 1272-1278 [PMID: 21212770 DOI: 10.1038/oby.2010.319]
131. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr 2007; 86: 353-359 [PMID: 17684205]
132. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 1998; 22: 1164-1171 [PMID: 9877251]
133. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991; 337: 382-386 [PMID: 1671422]
134. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002; 3: 141-146 [PMID: 12164465]
135. Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2000; 20: 1932-1938 [PMID: 10938014]
136. Katzmarzyk PT, Bray GA, Greenway FL, Johnson WD, Newton RL, Ravussin E, Ryan DH, Smith SR, Bouchard C. Racial differences in abdominal depot-specific adiposity in white and African American adults. Am J Clin Nutr 2010; 91: 7-15 [PMID: 19828714 DOI: 10.3945/ajcn.2009.28136]
137. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 1996; 45: 1119-1124 [PMID: 8781299]
138. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, El-Saed A, Miyamatsu N, Edmundowicz D, Kita Y, Sutton-Tyrrell K, Kuller LH, Ueshima H. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006; 30: 1163-1165 [PMID: 16446744]
139. Misra A, Khurana L. The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009; 7: 497-514 [PMID: 19900153 DOI: 10.1089/met.2009.002]
140. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overfow hypothesis. Int J Epidemiol 2007; 36: 220-225 [PMID: 17510078]
141. De Lorenzo A, Martinoli R, Vaia F, Di Renzo L. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis 2006; 16: 513-523 [PMID: 17126766]
142. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004; 89: 2569-2575 [PMID: 15181025]
143. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud' homme D, Rabasa-Lhoret R. The metabolically healthy but obese individual presents a favorable infammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150 [PMID: 15855252]
144. Seo MH, Rhee EJ. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul) 2014; 29: 427-434 [PMID: 25559571 DOI: 10.3803/EnM.2014.29.4.427]
145. Roubenoff R. Sarcopenic obesity: does muscle loss cause fat gain? Lessons from rheumatoid arthritis and osteoarthritis. Ann N Y Acad Sci 2000; 904: 553-557 [PMID: 10865804]
146. Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis 2014; 56: 426-433 [PMID: 24438734 DOI: 10.1016/j.pcad.2013.10.003]
147. De Lorenzo A, Del Gobbo V, Premrov MG, Bigioni M, Galvano F, Di Renzo L. Normal-weight obese syndrome: early infammation? Am J Clin Nutr 2007; 85: 40-45 [PMID: 17209175]
148. Kosmala W, Jedrzejuk D, Derzhko R, Przewlocka-Kosmala M, Mysiak A, Bednarek-Tupikowska G. Left ventricular function impairment in patients with normal-weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation. Circ Cardiovasc Imaging 2012; 5: 349-356 [PMID: 22407472 DOI: 10.1161/CIRCIMAGING.111.969956]
149. Marques-Vidal P, Pécoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, Vollenweider P. Normal weight obesity: relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr Metab Cardiovasc Dis 2010; 20: 669-675 [PMID: 19748248 DOI: 10.1016/j.numecd.2009.06.001]
150. Di Renzo L, Del Gobbo V, Bigioni M, Premrov MG, Cianci R, De Lorenzo A. Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci 2006; 10: 191-196 [PMID: 16910350]
151. Marques-Vidal P, Pécoud A, Hayoz D, Paccaud F, Mooser V, Waeber G, Vollenweider P. Prevalence of normal weight obesity in Switzerland: effect of various defnitions. Eur J Nutr 2008; 47: 251-257 [PMID: 18604623 DOI: 10.1007/s00394-008-0719-6]
152. Marques-Vidal P, Chiolero A. Paccaud F. Large differences in the prevalence of normal weight obesity using various cut-offs for excess body fat. E Spen Eur E J Clin Nutr Metab 2008; 3: e159-e162 [DOI: 10.1016/j.eclnm.2008.05.003]
153. Kyle UG, Genton L, Slosman DO, Pichard C. Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98 years. Nutrition 2001; 17: 534-541 [PMID: 11448570]
154. Kang S, Kyung C, Park JS, Kim S, Lee SP, Kim MK, Kim HK, Kim KR, Jeon TJ, Ahn CW. Subclinical vascular infammation in subjects with normal weight obesity and its association with body fat: an 18 F-FDG-PET/CT study. Cardiovasc Diabetol 2014; 13: 70 [PMID: 24708764 DOI: 10.1186/1475-2840-13-70]
155. Madeira FB, Silva AA, Veloso HF, Goldani MZ, Kac G, Cardoso VC, Bettiol H, Barbieri MA. Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country. PLoS One 2013; 8: e60673 [PMID: 23556000 DOI: 10.1371/journal.pone.0060673]
156. Kim JY, Han SH, Yang BM. Implication of high-body-fat percentage on cardiometabolic risk in middle-aged, healthy, normal-weight adults. Obesity (Silver Spring) 2013; 21: 1571-1577 [PMID: 23404833 DOI: 10.1002/oby.20020]
157. Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, Jensen MD, Parati G, Lopez-Jimenez F. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 2010; 31: 737-746 [PMID: 19933515 DOI: 10.1093/eurheartj/ehp487]
158. Jean N, Somers VK, Sochor O, Medina-Inojosa J, Llano EM, Lopez-Jimenez F. Normal-weight obesity: implications for cardiovascular health. Curr Atheroscler Rep 2014; 16: 464 [PMID: 25342492 DOI: 10.1007/s11883-014-0464-7]
159. Di Renzo L, Galvano F, Orlandi C, Bianchi A, Di Giacomo C, La Fauci L, Acquaviva R, De Lorenzo A. Oxidative stress in normal-weight obese syndrome. Obesity (Silver Spring) 2010; 18: 2125-2130 [PMID: 20339360 DOI: 10.1038/oby.2010.50]
160. Di Renzo L, Bigioni M, Del Gobbo V, Premrov MG, Barbini U, Di Lorenzo N, De Lorenzo A. Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels. Pharmacol Res 2007; 55: 131-138 [PMID: 17174563]
161. Di Renzo L, Bertoli A, Bigioni M, Del Gobbo V, Premrov MG, Calabrese V, Di Daniele N, De Lorenzo A. Body composition and-174G/C interleukin-6 promoter gene polymorphism: association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des 2008; 14: 2699-2706 [PMID: 18991689]
162. Di Renzo L, Bigioni M, Bottini FG, Del Gobbo V, Premrov MG, Cianci R, De Lorenzo A. Normal Weight Obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C-& gt; T genes in the relationship between body composition and resting metabolic rate. Eur Rev Med Pharmacol Sci 2006; 10: 235-245 [PMID: 17121316]
163. Di Renzo L, Gloria-Bottini F, Saccucci P, Bigioni M, Abenavoli L, Gasbarrini G, De Lorenzo A. Role of interleukin-15 receptor alpha polymorphisms in normal weight obese syndrome. Int J Immunopathol Pharmacol 2009; 22: 105-113 [PMID: 19309557]
164. Di Renzo L, Sarlo F, Petramala L, Iacopino L, Monteleone G, Colica C, De Lorenzo A. Association between-308 G/A TNF-α polymorphism and appendicular skeletal muscle mass index as a marker of sarcopenia in normal weight obese syndrome. Dis Markers 2013; 35: 615-623 [PMID: 24285913 DOI: 10.1155/2013/9834244]
165. Di Renzo L, Gratteri S, Sarlo F, Cabibbo A, Colica C, De Lorenzo A. Individually tailored screening of susceptibility to sarcopenia using p53 codon 72 polymorphism, phenotypes, and conventional risk factors. Dis Markers 2014; 2014: 743634 [PMID: 25371596 DOI: 10.1155/2014/743634]
166. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese, " normal-weight individual. Am J Clin Nutr 1981; 34: 1617-1621 [PMID: 7270486]
167. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 1998; 47: 699-713 [PMID: 9588440]
168. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999; 48: 2210-2214 [PMID: 10535456]
169. Conus F, Allison DB, Rabasa-Lhoret R, St-Onge M, St-Pierre DH, Tremblay-Lebeau A, Poehlman ET. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab 2004; 89: 5013-5020 [PMID: 15472199]
170. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91: 2906-2912 [PMID: 16735483]
171. Succurro E, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring) 2008; 16: 1881-1886 [PMID: 18551117 DOI: 10.1038/oby.2008.308]
172. Eckel N, Mühlenbruch K, Meidtner K, Boeing H, Stefan N, Schulze MB. Characterization of metabolically unhealthy normal-weight individuals: Risk factors and their associations with type 2 diabetes. Metabolism 2015; 64: 862-871 [PMID: 25861921 DOI: 10.1016/j.metabol.2015.03.009]
173. Du T, Yu X, Zhang J, Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype. Acta Diabetol 2015; 52: 855-863 [PMID: 25690647]
174. Lee SH, Han K, Yang HK, Kim MK, Yoon KH, Kwon HS, Park YM. Identifying subgroups of obesity using the product of triglycerides and glucose: the Korea National Health and Nutrition Examination Survey, 2008-2010. Clin Endocrinol (Oxf) 2015; 82: 213-220 [PMID: 24841432 DOI: 10.1038/nutd.2014.46]
175. Thomas EL, Frost G, Taylor-Robinson SD, Bell JD. Excess body fat in obese and normal-weight subjects. Nutr Res Rev 2012; 25: 150-161 [PMID: 22625426 DOI: 10.1017/S0954422412000054]
176. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004; 14: 228-232 [PMID: 15673055]
177. Bednarek-Tupikowska G, Zdrojowy-Wełna A, Stachowska B, Kuliczkowska-Płaksej J, Matczak-Giemza M, Kubicka E, Tworowska-Bardzinska U, Milewicz A, Bolanowski M. Accumulation of abdominal fat in relation to selected proinfammatory cytokines concentrations in non-obese Wrocław inhabitants. Endokrynol Pol 2014; 65: 449-455 [PMID: 25554612 DOI: 10.5603/EP.2014.0062]
178. Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. U-shaped and J-shaped relationships between serum insulin and coronary heart disease in the general population. The Bruneck Study. Diabetes Care 1998; 21: 221-230 [PMID: 9539986]
179. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism 2001; 50: 1499-1504 [PMID: 11735101]
180. van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, Doiron D, Fischer K, Foco L, Gaye A, Gögele M, Heier M, Hiekkalinna T, Joensuu A, Newby C, Pang C, Partinen E, Reischl E, Schwienbacher C, Tammesoo ML, Swertz MA, Burton P, Ferretti V, Fortier I, Giepmans L, Harris JR, Hillege HL, Holmen J, Jula A, Kootstra-Ros JE, Kvaløy K, Holmen TL, Männistö S, Metspalu A, Midthjell K, Murtagh MJ, Peters A, Pramstaller PP, Saaristo T, Salomaa V, Stolk RP, Uusitupa M, van der Harst P, van der Klauw MM, Waldenberger M, Perola M, Wolffenbuttel BH. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord 2014; 14: 9 [PMID: 24484869 DOI: 10.1186/1472-6823-14-9]
181. Yoo HK, Choi EY, Park EW, Cheong YS, Bae RA. Comparison of Metabolic Characteristics of Metabolically Healthy but Obese (MHO) Middle-Aged Men According to Different Criteria. Korean J Fam Med 2013; 34: 19-26 [PMID: 23372902 DOI: 10.4082/kjfm.2013.34.1.19]
182. Singh-Manoux A, Czernichow S, Elbaz A, Dugravot A, Sabia S, Hagger-Johnson G, Kaffashian S, Zins M, Brunner EJ, Nabi H, Kivimäki M. Obesity phenotypes in midlife and cognition in early old age: the Whitehall II cohort study. Neurology 2012; 79: 755-762 [PMID: 22915175 DOI: 10.1212/WNL.0b013e3182661f63]
183. Pajunen P, Kotronen A, Korpi-Hyövälti E, Keinänen-Kiukaanniemi S, Oksa H, Niskanen L, Saaristo T, Saltevo JT, Sundvall J, Vanhala M, Uusitupa M, Peltonen M. Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D Survey. BMC Public Health 2011; 11: 754 [PMID: 21962038 DOI: 10.1186/1471-2458-11-754]
184. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Crosignani P, Bosi E, Luzi L, Ruotolo G, Perseghin G. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011; 34: 210-215 [PMID: 20937689 DOI: 10.2337/dc10-0665]
185. Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, Rodriguez-Artalejo F. Prevalence and determinants of metabolically healthy obesity in Spain. Atherosclerosis 2013; 231: 152-157 [PMID: 24125427 DOI: 10.1016/j.atherosclerosis.2013.09.003]
186. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488 [PMID: 22508708 DOI: 10.1210/jc.2011-3475]
187. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86: 1020-1025 [PMID: 11238480]
188. Durward CM, Hartman TJ, Nickols-Richardson SM. All-cause mortality risk of metabolically healthy obese individuals in NHANES III. J Obes 2012; 2012: 460321 [PMID: 23304462 DOI: 10.1155/2012/460321]
189. Shea JL, Randell EW, Sun G. The prevalence of metabolically healthy obese subjects defined by BMI and dual-energy X-ray absorptiometry. Obesity (Silver Spring) 2011; 19: 624-630 [PMID: 20706202 DOI: 10.1038/oby.2010.174]
190. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab 2004; 30: 569-572 [PMID: 15671927]
191. Manu P, Ionescu-Tirgoviste C, Tsang J, Napolitano BA, Lesser ML, Correll CU. Dysmetabolic signals in "metabolically healthy" obesity. Obes Res Clin Pract 2012; 6: e1-e90 [PMID: 24331169 DOI: 10.1016/j.orcp.2011.04.003]
192. Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010; 121: 230-236 [PMID: 20038741 DOI: 10.1161/CIRCULATIONAHA.109.887521]
193. Flint AJ, Hu FB, Glynn RJ, Caspard H, Manson JE, Willett WC, Rimm EB. Excess weight and the risk of incident coronary heart disease among men and women. Obesity (Silver Spring) 2010; 18: 377-383 [PMID: 19629058 DOI: 10.1038/oby.2009.223]
194. Eshtiaghi R, Keihani S, Hosseinpanah F, Barzin M, Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes (Lond) 2015; 39: 514-519 [PMID: 25287753 DOI: 10.1038/ijo.2014.176]
195. Shaharyar S, Roberson LL, Jamal O, Younus A, Blaha MJ, Ali SS, Zide K, Agatston AA, Blumenthal RS, Conceição RD, Santos RD, Nasir K. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are signifcantly associated with prevalenceof elevated C-reactive protein and hepatic steatosis in a large healthy brazilian population. J Obes 2015; 2015: 178526 [DOI: 10.1155/2015/178526]
196. Achilike I, Hazuda HP, Fowler SP, Aung K, Lorenzo C. Predicting the development of the metabolically healthy obese phenotype. Int J Obes (Lond) 2015; 39: 228-234 [PMID: 24984752 DOI: 10.1038/ijo.2014.113]
197. Puri R. Is it fnally time to dispel the concept of metabolically-healthy obesity? J Am Coll Cardiol 2014; 63: 2687-2688 [PMID: 24794116 DOI: 10.1016/j.jacc.2014.03.043]
198. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, Zhao D, Jung HS, Choi Y, Ahn J, Lima JA, Shin H, Guallar E, Ryu S. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol 2014; 63: 2679-2686 [PMID: 24794119 DOI: 10.1016/j.jacc.2014.03.042]
199. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-769 [PMID: 24297192 DOI: 10.7326/0003-4819-159-11-201312030-00008]
200. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012; 126: 1301-1313 [PMID: 22949540 DOI: 10.1161/CIRCULATIONAHA.111.067264]
201. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-A new worldwide defnition. Lancet 2005; 366: 1059-1062 [PMID: 16182882]
202. Di Daniele N, Petramala L, Di Renzo L, Sarlo F, Della Rocca DG, Rizzo M, Fondacaro V, Iacopino L, Pepine CJ, De Lorenzo A. Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean Diet in obese patients with metabolic syndrome. Acta Diabetol 2013; 50: 409-416 [PMID: 23188216 DOI: 10.1007/s00592-012-0445-7]
203. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622 [PMID: 22055504 DOI: 10.1016/j.cmet.2011.10.002]
204. Alberti KG, Zimmet PZ. Defnition, diagnosis and classifcation of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553 [PMID: 9686693]
205. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752 [PMID: 16157765]
206. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497 [PMID: 11368702]
207. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH. The diet and 15-year death rate in the seven countries study. Am J Epidemiol 1986; 124: 903-915 [PMID: 3776973]
208. Wycherley TP, Brinkworth GD, Clifton PM, Noakes M. Comparison of the effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body composition and cardiometabolic risk factors in overweight and obese males. Nutr Diabetes 2012; 2: e40 [PMID: 23448804 DOI: 10.1038/nutd.2012.11]
209. Teixeira TF, Alves RD, Moreira AP, Peluzio Mdo C. Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes. Nutr Rev 2015; 73: 175-190 [PMID: 26024540 DOI: 10.1093/nutrit/nuu007]
210. O'Connell J, Lynch L, Cawood TJ, Kwasnik A, Nolan N, Geoghegan J, McCormick A, O'Farrelly C, O'Shea D. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One 2010; 5: e9997 [PMID: 20376319 DOI: 10.1371/journal.pone.0009997]
211. Calanna S, Piro S, Di Pino A, Maria Zagami R, Urbano F, Purrello F, Maria Rabuazzo A. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis. Obesity (Silver Spring) 2013; 21: 320-325 [PMID: 23404781 DOI: 10.1002/oby.20017]
212. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 424-431 [PMID: 18242210 DOI: 10.1053/j.gastro.2007.11.038]
213. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382]
214. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008; 134: 1369-1375 [PMID: 18355813 DOI: 10.1053/j.gastro.2008.01.075]
215. Roberts R, Hodson L, Dennis AL, Neville MJ, Humphreys SM, Harnden KE, Micklem KJ, Frayn KN. Markers of de novo lipogenesis in adipose tissue: associations with small adipocytes and insulin sensitivity in humans. Diabetologia 2009; 52: 882-890 [PMID: 19252892 DOI: 10.1007/s00125-009-1300-4]
216. Herman MA, Peroni OD, Villoria J, Schön MR, Abumrad NA, Blüher M, Klein S, Kahn BB. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012; 484: 333-338 [PMID: 22466288 DOI: 10.1038/nature10986]
217. Hoffstedt J, Förster D, Löfgren P. Impaired subcutaneous adipocyte lipogenesis is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio in men and women. J Intern Med 2007; 262: 131-139 [PMID: 17598821]
218. Kursawe R, Eszlinger M, Narayan D, Liu T, Bazuine M, Cali AM, D'Adamo E, Shaw M, Pierpont B, Shulman GI, Cushman SW, Sherman A, Caprio S. Cellularity and adipogenic profile of the abdominal subcutaneous adipose tissue from obese adolescents: association with insulin resistance and hepatic steatosis. Diabetes 2010; 59: 2288-2296 [PMID: 20805387 DOI: 10.2337/db10-0113]
219. Graham TE, Kahn BB. Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes. Horm Metab Res 2007; 39: 717-721 [PMID: 17952832]
220. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-3497 [PMID: 17595248]
221. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-728 [PMID: 18939388]
222. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010; 91: 1123S-1127S [PMID: 20164314 DOI: 10.3945/ajcn.2010.28608A]
223. Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol 2013; 2013: 204164 [PMID: 23690769 DOI: 10.1155/2013/204164]
224. Frühbeck G. The Sir David Cuthbertson Medal Lecture. Hunting for new pieces to the complex puzzle of obesity. Proc Nutr Soc 2006; 65: 329-347 [PMID: 17181900]
225. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Pérusse L, Bouchard C. The human obesity gene map: the 2005 update. Obesity (Silver Spring) 2006; 14: 529-644 [PMID: 16741264]
226. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423 [PMID: 20392703 DOI: 10.1093/ageing/afq034]
227. Schrager MA, Metter EJ, Simonsick E, Ble A, Bandinelli S, Lauretani F, Ferrucci L. Sarcopenic obesity and infammation in the InCHIANTI study. J Appl Physiol (1985) 2007; 102: 919-925 [PMID: 17095641]
228. Silva AO, Karnikowski MG, Funghetto SS, Stival MM, Lima RM, de Souza JC, Navalta JW, Prestes J. Association of body composition with sarcopenic obesity in elderly women. Int J Gen Med 2013; 6: 25-29 [PMID: 23378781 DOI: 10.2147/IJGM. S36279]
229. De Lorenzo A, Di Renzo L, Puja A, Saccucci P, Gloria-Bottini F, Bottini E. A study of acid phosphatase locus 1 in women with high fat content and normal body mass index. Metabolism 2009; 58: 351-354 [PMID: 19217450 DOI: 10.1016/j.metabol.2008.10.007]
230. Hsu FC, Lenchik L, Nicklas BJ, Lohman K, Register TC, Mychaleckyj J, Langefeld CD, Freedman BI, Bowden DW, Carr JJ. Heritability of body composition measured by DXA in the diabetes heart study. Obes Res 2005; 13: 312-319 [PMID: 15800289]
231. Prado CM, Siervo M, Mire E, Heymsfield SB, Stephan BC, Broyles S, Smith SR, Wells JC, Katzmarzyk PT. A population-based approach to define body-composition phenotypes. Am J Clin Nutr 2014; 99: 1369-1377 [PMID: 24760978 DOI: 10.3945/ajcn.113.078576]
232. Prado CM, Heymsfeld SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enteral Nutr 2014; 38: 940-953 [PMID: 25239112 DOI: 10.1177/0148607 114550189]
233. Kral JG, Kava RA, Catalano PM, Moore BJ. Severe obesity: the neglected epidemic. Obes Facts 2012; 5: 254-269 [PMID: 22647306 DOI: 10.1159/000338566]
234. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752 [PMID: 17715408]
235. Mitka M. Bariatric surgery continues to show benefts for patients with diabetes. JAMA 2012; 307: 1901-1902 [PMID: 22570449 DOI: 10.1001/jama.2012.3727]
236. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132: 2253-2271 [PMID: 17498516]
237. Pontiroli AE, Pizzocri P, Librenti MC, Vedani P, Marchi M, Cucchi E, Orena C, Paganelli M, Giacomelli M, Ferla G, Folli F. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 3555-3561 [PMID: 12161474]
238. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10: 233-239 [PMID: 10929154]
239. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753-761 [PMID: 17715409]
240. Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 2011; 28: 628-642 [PMID: 21480973 DOI: 10.1111/j.1464-5491.2011.03306. x]
241. Ramalho R, Guimarães C. [The role of adipose tissue and macrophages in chronic inflammation associated with obesity: clinical implications]. Acta Med Port 2008; 21: 489-496 [PMID: 19187692]
242. Ramalho R, Guimarães C, Gil C, Neves C, Guimarães JT, Delgado L. Morbid obesity and infammation: a prospective study after adjustable gastric banding surgery. Obes Surg 2009; 19: 915-920 [PMID: 19440803 DOI: 10.1007/s11695-009-9848-0]
243. Weiss R, Appelbaum L, Schweiger C, Matot I, Constantini N, Idan A, Shussman N, Sosna J, Keidar A. Short-term dynamics and metabolic impact of abdominal fat depots after bariatric surgery. Diabetes Care 2009; 32: 1910-1915 [PMID: 19587363 DOI: 10.2337/dc09-0943]
244. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737 [PMID: 15479938]
245. Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 4206-4210 [PMID: 15356007]
246. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-59 [PMID: 3796297]
247. Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 2005; 28: 2322-2325 [PMID: 16123512]
248. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999; 48: 839-847 [PMID: 10102702]
249. Carroll JF, Franks SF, Smith AB, Phelps DR. Visceral adipose tissue loss and insulin resistance 6 months after laparoscopic gastric banding surgery: a preliminary study. Obes Surg 2009; 19: 47-55 [PMID: 18663543 DOI: 10.1007/s11695-008-9642-4]
250. Korner J, Punyanitya M, Taveras C, McMahon DJ, Kim HJ, Inabnet W, Bessler M, Gallagher D. Sex differences in visceral adipose tissue post-bariatric surgery compared to matched non-surgical controls. Int J Body Compos Res 2008; 6: 93-99 [PMID: 20582247]
251. Toro-Ramos T, Goodpaster BH, Janumala I, Lin S, Strain GW, Thornton JC, Kang P, Courcoulas AP, Pomp A, Gallagher D. Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. Obesity (Silver Spring) 2015; 23: 62-69 [PMID: 25384375 DOI: 10.1002/oby.20932]
252. Benaiges D, Goday A, Ramon JM, Hernandez E, Pera M, Cano JF; Obemar Group. Laparoscopic sleeve gastrectomy and laparoscopic gastric bypass are equally effective for reduction of cardiovascular risk in severely obese patients at one year of follow-up. Surg Obes Relat Dis 2011; 7: 575-580 [PMID: 21546321 DOI: 10.1016/j.soard.2011.03.002]
253. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 2006; 91: 4223-4231 [PMID: 16954156]
254. Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, Wolfe LG. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003; 7: 102-107; discussion 107-108 [PMID: 12559191]
255. Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003; 112: 409-413 [PMID: 12589429]
256. Moleres A, Rendo-Urteaga T, Azcona C, Martínez JA, Gómez-Martínez S, Ruiz JR, Moreno LA, Marcos A, Marti A. Il6 gene promoter polymorphism (-174G/C) influences the association between fat mass and cardiovascular risk factors. J Physiol Biochem 2009; 65: 405-413 [PMID: 20358354 DOI: 10.1007/BF03185936]
257. Möhlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 1885-1890 [PMID: 15070960]
258. Di Renzo L, Carbonelli MG, Bianchi A, Iacopino L, Fiorito R, Di Daniele N, De Lorenzo A. Body composition changes after laparoscopic adjustable gastric banding: what is the role of-174G& gt; C interleukin-6 promoter gene polymorphism in the therapeutic strategy? Int J Obes (Lond) 2012; 36: 369-378 [PMID: 21730965 DOI: 10.1038/ijo.2011.132]
259. Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012; 271: 111-121 [PMID: 22142401 DOI: 10.1111/j.1365-2796.2011.02498.x]